Who are Advil PM Liqui-Gels Minis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Celebrex, Cytotec, Bromfenac 0.075% Oph Solution, Voltaren® Gel, Acetylsalicylic Acid + clopidogrel + acenocoumarol, VIMOVO 250/20.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/advil-pm-liqui-gels-minis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Advil PM Liqui-Gels Minis — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advil PM Liqui-Gels Minis (Advil PM Liqui-Gels Minis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain Management.

phase 1 NSAID COX Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Advil PM Liqui-Gels Minis (Advil PM Liqui-Gels Minis) — HALEON. Acetaminophen is a non-selective COX inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Advil PM Liqui-Gels Minis TARGET	Advil PM Liqui-Gels Minis	HALEON	phase 1	NSAID	COX
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Bromfenac 0.075% Oph Solution	Bromfenac 0.075% Oph Solution	Carolina Eyecare Physicians, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Voltaren® Gel	Voltaren® Gel	Glenmark Pharmaceuticals Ltd. India	marketed	Topical NSAID	COX-1 and COX-2 enzymes
Acetylsalicylic Acid + clopidogrel + acenocoumarol	Acetylsalicylic Acid + clopidogrel + acenocoumarol	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase (COX), P2Y12 receptor, Vitamin K-dependent clotting factors
VIMOVO 250/20	VIMOVO 250/20	Amgen	marketed	NSAID with proton pump inhibitor combination	COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-05-27 — Celebrex · 10722456 · Formulation · US
2036-05-27 — Celebrex · 10799517 · Formulation · US
2036-05-27 — Celebrex · 9949990 · Formulation · US
2036-05-27 — Celebrex · 9795620 · Formulation · US
2036-05-27 — Celebrex · 9572819 · Formulation · US
2036-05-27 — Celebrex · 10376527 · Formulation · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Advil PM Liqui-Gels Minis — Competitive Intelligence Brief. https://druglandscape.com/ci/advil-pm-liqui-gels-minis. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab